Compare GD & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GD | SNY |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.1B | 113.9B |
| IPO Year | 2006 | N/A |
| Metric | GD | SNY |
|---|---|---|
| Price | $308.64 | $46.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $375.33 | $58.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | 1.92% | ★ 3.48% |
| EPS Growth | ★ 13.35 | N/A |
| EPS | ★ 15.45 | N/A |
| Revenue | ★ $52,550,000,000.00 | N/A |
| Revenue This Year | $7.38 | $3.49 |
| Revenue Next Year | $4.50 | $6.10 |
| P/E Ratio | $20.20 | ★ $6.14 |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $266.98 | $43.32 |
| 52 Week High | $369.70 | $55.73 |
| Indicator | GD | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 23.26 | 43.66 |
| Support Level | $306.03 | $45.20 |
| Resistance Level | $324.75 | $48.79 |
| Average True Range (ATR) | 6.90 | 0.75 |
| MACD | -2.84 | -0.21 |
| Stochastic Oscillator | 3.71 | 6.59 |
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments are aerospace, marine, combat systems, and technologies. General Dynamics' aerospace segment manufactures Gulfstream business jets and operates a global aircraft servicing operation. Combat systems produces land-based combat vehicles such as the M1 Abrams tank and Stryker armored personnel carrier, as well as munitions. The marine segment builds and services nuclear-powered submarines, destroyers, and Navy support ships. The technologies segment contains two main units: an IT business that primarily serves the government market and a mission systems business focusing on electronics that provide command, control, computing, intelligence, surveillance, and reconnaissance capabilities to the military.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.